ADMA(ADMA Biologics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $80.94M | $154.08M | $258.21M | $426.45M | $510.17M |
| 毛利润 | $1.17M | $35.27M | $88.94M | $219.55M | $292.76M |
| 营业利润 | −$58.37M | −$39.37M | $21.63M | $138.98M | $191.44M |
| 净利润 | −$71.65M | −$65.90M | −$28.24M | $197.67M | $146.93M |
| 经营现金流 | −$112.37M | −$59.51M | $8.80M | $118.67M | $50.40M |
| 自由现金流 | −$125.88M | −$73.42M | $4.03M | $110.45M | $27.82M |
| 摊薄每股收益 | $-0.51 | $-0.33 | $-0.13 | $0.81 | $0.60 |